The promise of N-methyl-D-aspartate receptor antagonists in fibromyalgia
2002 (English)In: Rheumatic Disease Clinics of North America, ISSN 0889-857X, Vol. 28, no 2, 343-351 p.Article in journal (Refereed) Published
There is strong evidence that intravenous administration of ketamine following a standardized protocol could be used as a diagnostic test for a central sensitization in the central nervous system in patients with FM. The combination of a weak opioid and an NMDA-receptor antagonist with few side effects is presently a promise for treatment of pain in a subgroup of patients with FM. The response to intravenously administered ketamine may help select patients for this treatment modality.
Place, publisher, year, edition, pages
2002. Vol. 28, no 2, 343-351 p.
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-27814DOI: 10.1016/S0889-857X(01)00013-8Local ID: 12566OAI: oai:DiVA.org:liu-27814DiVA: diva2:248366